Results 201 to 210 of about 1,868 (233)
Some of the next articles are maybe not open access.
Exploration and evaluation of adverse event signals of droxidopa based on the FAERS database.
Expert Opinion on Drug SafetyBACKGROUND This study aims to utilize the FDA's Adverse Event Reporting System (FAERS) for data analysis to explore the potential adverse events associated with Droxidopa in real-world settings, thereby providing reference information for clinical ...
Xinnan Chen+3 more
semanticscholar +1 more source
L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension
Clinical Autonomic Research, 2008Neurogenic orthostatic hypotension is a cardinal feature of generalised autonomic failure and commonly is the presenting sign in patients with primary autonomic failure. Orthostatic hypotension can result in considerable morbidity and even mortality and is a major management problem in disorders such as pure autonomic failure, multiple system atrophy ...
Christopher J. Mathias+1 more
openaire +3 more sources
Analytical Chemistry Letters
Background: Droxidopa, a prodrug for neurogenic orthostatic hypotension, requires precise quality analysis. RP-HPLC is valued for its sensitivity and reliability in pharmaceutical quality control, but traditional methods are time-consuming and lack ...
Sandhya Madhuri Maddala+2 more
semanticscholar +1 more source
Background: Droxidopa, a prodrug for neurogenic orthostatic hypotension, requires precise quality analysis. RP-HPLC is valued for its sensitivity and reliability in pharmaceutical quality control, but traditional methods are time-consuming and lack ...
Sandhya Madhuri Maddala+2 more
semanticscholar +1 more source
DBH deficiency in an elderly patient: efficacy and safety of chronic droxidopa
Clinical Autonomic Research, 2010We describe the effects of chronic droxidopa in a patient with Dopamine beta-hydroxylase deficiency diagnosed at the age of 73. Investigations were performed to assess sympathetic activity (MIBG scintigraphy, catecholamines) and cardiovascular droxidopa safety.
P. Massabuau+11 more
openaire +3 more sources
Droxidopa: A Review of Its Use in Symptomatic Neurogenic Orthostatic Hypotension
Drugs, 2015The norepinephrine prodrug droxidopa (NORTHERA™) is approved in the US for the treatment of orthostatic dizziness, lightheadedness, or the 'feeling that you are about to black out' in adults with symptomatic neurogenic orthostatic hypotension associated with primary autonomic failure (e.g.
exaly +4 more sources
[Study on the metabolism of droxidopa in humans].
Rinsho shinkeigaku = Clinical neurology, 1995Supplement of the deficient neurotransmitters is one of the most effective therapies for neurodegenerative disorders. For the treatment of Parkinson's disease, L-DOPA therapy has been applied to replace dopamine, and droxidopa (L-threo-3,4-dihydroxyphenylserine) therapy to supply noradrenaline (NA).
W, Maruyama, M, Naoi, H, Narabayashi
openaire +1 more source
Droxidopa for the Treatment of Parkinson’s Disease
2020Mizuki Ito, Hirohisa Watanabe
openaire +1 more source
Droxidopa reduces postural sway in Parkinson disease patients with orthostatic hypotension.
Parkinsonism & Related Disorders, 2022L. Marsili+7 more
semanticscholar +1 more source